Agreement with Israel's leading orthopedics distributor includes minimum purchase commitments; Revenue contributions expected to begin during 2027AMI Technologies brings an established orthopedic sales and
Engagement with leading orthopedic surgeons and cartilage repair specialists highlights growing awareness of GelrinC's off-the-shelf regenerative technologyGelrinC is CE Mark approved in Europe, where Regentis is
HERZLIYA, IL / ACCESS Newswire / October 9, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE:RGNT), a regenerative medicine company focused on innovative tissue repair solutions,
AUSTIN, Texas, Sept. 18, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the
Advances GelrinC® U.S. pivotal trial with 43 patients treated; Completion of enrollment expected by approximately year end 2026Expands European commercialization readiness, including surgeon training and regulatory
Patent expands intellectual property protection in one of the world's largest cartilage repair marketsGelrinC is a cell-free hydrogel delivered in a single ~10-minute procedure eliminating the need for cell
European Notified Body approves next-generation manufacturing process that increases production 5-fold, lowers manufacturing costs, improves safety and enables scalable commercial productionGelrinC®, which is approved
HERZLIYA, IL / ACCESS Newswire / June 17, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced that
GelrinC®, positioned as the first off-the-shelf cell-free hydrogel implant for knee cartilage repair, is approved for sale in the European UnionRegentis is growing its network of European Centers of Excellence
Collaboration with leading European orthopedic center in Italy supports GelrinC® clinical adoptionRenowned cartilage regeneration expert Prof. Elizaveta Kon to help lead Regentis Centers of Excellence
Breakthrough manufacturing process comes in preparation for upcoming commercial launch in Europe planned for later this yearProprietary process is already patented in several countries and is pending in the U.S.HERZLIYA,
$7.4 million in cash expected to provide runway to complete site expansion process and patient enrollment as part of pivotal Phase III FDA trial for GelrinCAlready approved in Europe, GelrinC is expected to be rolled out
Dr. Reske has proven leadership in clinical development and regulatory affairs following key role in FDA approval of cartilage repair product Agili-C leading to CartiHeal's $330 million acquisitionHERZLIYA, ISRAEL /
With CE Mark approval, GelrinC is slated for commercial launch in Europe in 2026New clinical sites to support engagement with leading orthopedic surgeons and centers of excellence in key European markets, strengthening
GelrinC, the only restorative product for knee cartilage repair, has CE Mark approval in Europe and is currently at the midpoint of a pivotal FDA Phase III trial in the U.S.Ori Gon brings substantial public company,
